logo
Plus   Neg
Share
Email

Eli Lilly Says Dulaglutide Meets Primary Endpoint - Quick Facts

Eli Lilly and Co. (LLY) announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1, or GLP-1, analog being studied as a once-weekly treatment for type 2 diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure after 16 weeks.

According to the company, the results came from a Phase II study that compared two doses of dulaglutide to placebo, using ambulatory blood pressure monitoring to characterize changes in blood pressure and heart rate. Also, the 1.5 mg dulaglutide dose significantly reduced mean 24-hour SBP compared to placebo.

Gwen Krivi, vice president, product development, Lilly Diabetes, said, "We are very encouraged by these clinical trial results, in addition to the rest of the clinical trial data we've seen to date for dulaglutide. Dulaglutide is currently in Phase III clinical trials, where it will continue to be evaluated on its efficacy to lower blood glucose levels, overall safety, weight effects and effects on cardiovascular outcomes. We believe dulaglutide, if approved, can bring significant benefits to people with type 2 diabetes."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported that its first-quarter comparable earnings per share from continuing operations grew 8% year-over-year to $0.47. On average, 20 analysts polled by Thomson Reuters expected the company to report profit per share of $0.46 for the quarter. Analysts' estimates typically... Eli Lilly and Co. (LLY) Tuesday reported a profit for its first-quarter, compared to a loss last year, primarily driven by higher operating income. Quarterly revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products. The company raised its 2018 outlook. Both adjusted earnings per share and revenue for the quarter beat analysts' expectations. Shares of SAP SE were gaining around 3 percent in German trading after the software giant reported Tuesday higher first-quarter profit with strong growth in cloud subscriptions and support revenues. The company further lifted its outlook for fiscal 2018. CEO said, "With an increasing share of predictable revenues, our beyond expectations profitability is cause for even greater shareholder confiden
Follow RTT